CLINICAL EXPERIENCE WITH CEFTIZOXIME IN THE TREATMENT OF PULMONARY INFECTIONS

• Published in: CHEMOTHERAPY Vol. 28; no. Supplement5; pp. 161 - 168
• Main Authors: YOSHIDA, TSUKASA, TAMURA, TOYOKAZU, YAOI, HIROYOSHI, KAWANA, RINJI, YOSHIDA, TAKESHI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 01.01.1980
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.28.Supplement5_161

Ceftizoxime therapy was performed in 7 cases of pulmonary infections including 5 cases with acute pneumonia, one with acute broncho pneumonia and one with pulmonary tuberculosis who was tentatively diagnosed as acute pneumonia on the first examination. In every case, ceftizoxime was administered 1g in 300 ml of 5% xylitol by drip infusion method twice a day for 8 to 15 days. Minimum inhibitory concentrations (MIC) of clinically isolated organisms (may be causative) were determined for ceftizoxime and cefazolin, and radiographic examination of the chest was made as well as other laboratory examinations including routine haematology and urinalysis. The overall clinical efficacy of each case was rated on a five-step scale (marked, moderate, slight, poor and unevaluable) according primarily to degree of improvement in chest X-ray photograph and bacteriological effect from sputum and also by reference to other laboratory findings, subjective symptoms including adverse reactions. Clinical response was marked in one case and moderate in 5 cases, whereas unevaluable case in one with pulmonary tuberculosis. A substantial contraction or disappearance of opacities on chest X-ray photograph was attained following ceftizoxime therapy in all cases except one case of pulmonary tuberculosis. MICs of Haemophilus influenza., Haemophilus parainfluenzae, Streptococcus pneumonia. and Enterobacter isolated as causative organisms from sputum were 0.025 to 1.56μg/ml at the inoculum size of 106 cells/ml and 0.05 to 3.13μg/ml at 108/ml. All these organisms disappeared following ceftizoxime therapy. Adverse reactions occurred in one case; fever and anxiety developed on the 6 th day of ceftizoxime therapy, which subsequent feeling of chest distress, anorexia, diarrhea, nausea and vomiting, which all disappeared on the next day of the drug discontinuation.